Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. - Wikidata - wikimedia - TriplyDB

Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.

Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.

http://www.wikidata.org/entity/Q34631965

about

Tumor markers for hepatocellular carcinoma (Review)Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation Hepatocellular Cancer: New Kids on the Block Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy.Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy.Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.The diagnosis and treatment of hepatocellular carcinoma.Clinical applications of capillary electrophoresis based immunoassays.Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma.Biomarkers in hepatocellular carcinoma: an overview.The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma.Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012.Early Detection of Hepatocellular Carcinoma Recurrence Using the Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein.Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma.Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A.Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.Recent topics on α-fetoprotein.

P2860

Q24608195-8B3F37C1-7729-4E17-A043-CEA238C4BAB7 Q26772329-7A1FF46E-C2BB-464A-A011-F22D2D071C1A Q27022642-9BD85C39-6B1E-4A3B-81F9-EDD4DDC353F8 Q33913585-058CD2E5-BFCE-491E-A1CA-DC091FDE5D9D Q36378791-3043EC3C-795D-470E-90A7-C42DEB234BBC Q37351966-5E0B05E8-81D8-4997-8226-07CD1BE41E00 Q37534070-E0298E34-6E68-4E47-B21E-CA72C93425F6 Q37642297-07233983-4A5D-445D-8565-3C6828322D4E Q37684562-C7A84713-2DAF-4A3C-842A-B65D7AB017DD Q37972808-27E9D6BD-AD2C-4668-A0D0-35F6AF9642F5 Q39202758-D62A1807-B782-4A7A-B18C-850F4BF18C15 Q39403724-A52C44B0-E879-43E5-A5F5-0F9BE1A495F8 Q39674275-0CF86428-7882-42D0-B12F-80DB0B671DFA Q41717451-3E72F872-53F4-49A5-A66F-4942136E63F6 Q41874033-BE3175BA-42D8-48B7-8AE5-A6CA868295CD Q42254863-E39101E3-19C0-4A3D-80E1-C6625C853AC3 Q48118439-CDEE271B-A35B-47BC-983C-4BDBE3AC118E Q51063243-04811A82-746B-42A4-9C60-A3BF4C2AE07D Q53123123-C057B90A-FAB3-475F-AED2-A735F06BED20

P2860

Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.

http://www.wikidata.org/entity/Q34631965

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@ast

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@en

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@nl

type

label

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@ast

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@en

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@nl

prefLabel

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@ast

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@en

Highly sensitive AFP-L3% assay ...... ment pre- and postoperatively.

@nl

P1433

Q34631965-7DCE3051-494E-4F97-A7E5-8B29526F484D

P1476

Q34631965-80DF5A77-B328-47CC-9AFE-8CFB7BCF431C

P2093

Q34631965-0D87CCD7-023B-40C1-ABD5-F0EEB881C9EE

Q34631965-3E102E4F-F825-4C0B-AA8F-4A4930E6D66B

Q34631965-54B724EC-77E4-4269-ABBA-98B256E33460

Q34631965-6E9F797B-D31C-4969-9D11-7E5D26366A50

Q34631965-816A44A5-7281-44D2-AADB-EE3F9536B1DD

Q34631965-974398F9-B78E-4DD7-996B-91304F7BAEAE

Q34631965-A1B680E0-02DB-4285-B62C-F17DF7267BF6

Q34631965-A3AA0F25-F7E5-4428-AAAE-D59D8D60815D

Q34631965-B50C6E56-3436-432B-B716-8BD3713B75A2

Q34631965-C4735428-AAB2-4545-A7C6-30A606882FF0

P2860

Q34631965-220D5BB6-8E45-4019-8F55-CC2E16DBDEEF

Q34631965-2D85D3F1-AADC-4F8C-B3C3-984F072277F2

Q34631965-2F2B2D46-8ECA-4704-A56B-3A37FA0B2E8F

Q34631965-32EEF2DF-3A87-4B56-9630-540E03E03ADF

Q34631965-4F21C144-6EBA-47C0-ADB8-CA37BC67C580

Q34631965-54962C64-B652-4BFD-92B1-15D9A9A66AA8

Q34631965-5B1D100B-242A-490C-9A4A-442748C57462

Q34631965-71F3E5FE-F9B6-44CA-91A7-E2F6A8582259

Q34631965-ABCBA999-9EBB-46D7-847C-EF94E133DF85

Q34631965-C6371A59-0A90-4730-93BE-DA5F482736FF

P304

Q34631965-AFB85E76-0A37-40A4-BF27-6D5AD5C4BE16

P31

Q34631965-1317F553-D02D-4488-A4C4-79E2E92D7214

P356

Q34631965-6388A29B-8831-42F7-98C6-C20BDB30979E

P433

Q34631965-E8455859-2886-4A88-9463-FD1A8798BDA4

P478

Q34631965-88A1B7C0-77AA-43BF-85B1-F21A38893F62

P50

Q34631965-87A738B5-2257-46AD-817A-D25B9AF22402

P577

Q34631965-949505D3-AC46-48F3-B4B7-93EDE0ABBD7D

P698

Q34631965-6DBC659A-D4B1-424C-81B4-8BFEFF6887D3

P356

J.1872-034X.2011.00858.X

P1433

Hepatology Research

P1476

Highly sensitive AFP-L3% assay ...... tment pre- and postoperatively

@en

P2093

Fumitaka Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Kumada

http://www.w3.org/2001/XMLSchema#string

Hitomi Sezaki

http://www.w3.org/2001/XMLSchema#string

Kenji Ikeda

http://www.w3.org/2001/XMLSchema#string

Masahiro Kobayashi

http://www.w3.org/2001/XMLSchema#string

Norio Akuta

http://www.w3.org/2001/XMLSchema#string

Satoshi Saitoh

http://www.w3.org/2001/XMLSchema#string

Yasuji Arase

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Suzuki

http://www.w3.org/2001/XMLSchema#string

Yusuke Kawamura

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Cancer statistics, 2008

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis.

Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.

Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B.

Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.

P304

1036-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1872-034X.2011.00858.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21883741

http://www.w3.org/2001/XMLSchema#string